1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
19 |
20 |
21 |
22 |
23 |
24 |
25 |
26 |
27 |
28 |
29 |
30 |
31 |
32 |
33 |
34 |
35 |
36 |
37 |
38 |
39 |
40 |
41 |
42 |
43 |
44 |
45 |
46 |
47 |
48 |
49 |
50 |
51 |
52 |
53 |
54 |
55 |
RECIST Response Tested for First TC-210 in Advanced Mesothelin – Expressing Solid Tumors
Release Date: 15 July 2020
Recently, a biopharmaceutical company TCR2 Therapeutics was focused towards testing the response of TC-210 for the treatment of aadvanced mesothelin expressing solid tumors. With the primary aim of identifying the safety profile of TC-210 in patients having mesotheli...
Read More
Imbruvica and Rituximab Combination given a Positive Response from European Medicines Agency (EMA) for the Treatment of Chronic Lymphocytic Leukaemia (CLL)
Release Date: 15 July 2020
The drug Ibrutinib in combination with another drug called as Rituximab is now considered as an important novel targeted and non-chemotherapeutic treatment option for the patients suffering from CLL. The following has been represented by bio-pharmaceutical company Ja...
Read More
CRISPR Cas9 Gene Editing Market Presents USD 2 Billion Market Opportunity
Release Date: 04 January 2020
The report “Global CRISPR Cas9 Market, Clinical Trials and Therapeutic Application Outlook 2024” specifies the breathless advances in the genetic engineering that became possible due to CRISPR technology. The...
Read More
Cancer Tumor Organoids To Transform Cancer Therapy Market With USD 400 Million Opportunity
Release Date: 04 January 2020
In cancer biology, an important aspect of developing a personalized anti-cancer therapy is by reconstructing the heterogeneity in the cancer models with respect to the specific patient. All along, the emergence of cancer organoids as an ...
Read More
Cancer Organoid Approach To Drive Personalized Cancer Drug Development
Release Date: 03 January 2020
Although several technologies are available to predict the response to the cancer treatments but all of the available technologies revolves around a negative loop eventually. The negative loops present in the already available technologi...
Read More
Cancer Organoid Approach for Transforming Human Cancer Modeling
Release Date: 02 January 2020
For a very long time, the prediction of accurate treatment response in the patients was considered as a day-dream among the researchers. Although several technologies are available for predicting the treatment response, but the discovery...
Read More
Cancer Organoid Modeling Offers USD 400 Million Opportunity
Release Date: 02 January 2020
Cancer organoids is a versatile technology that aims at developing the models of in vivo organs of humans and with such advancements it enables the researchers to study about the cancer development and progression as well as the predicti...
Read More
Tumor Organoids to Drive Personalized Cancer Treatment Market
Release Date: 02 January 2020
The current scenario of the medical world represents the boundation by the constructs of the very traditional models for the care delivery and the limitation for the doctors to prescribe the therapies that are based on population average...
Read More
US Fecal Microbiota Transplant Market – Rapidly Expanding Segment of Healthcare Sector
Release Date: 10 October 2019
Although various therapeutics are currently available in the market but all have some drawbacks, which results in development new therapeutic approaches such as microbiome based therapy. The use of microbiome as a novel therapeutic appro...
Read More
Indian Breast Pump Market Witnessing Exponential Growth
Release Date: 10 October 2019
Lifestyle of modern mothers is full of stress and work load and hence they are not able to spend the quality time with their babies, which results in improper breastfeeding pattern. This result in development of health complications in m...
Read More
Cancer Stem Cell Therapeutics An innovative Approach for Cancer Treatment
Release Date: 09 October 2019
Although several therapies are available for the management of cancer but all of them have their own drawbacks, which generates instant need of development of noval therapeutics. One of the recently developed approaches involves utilizat...
Read More
CAR T-Cell Therapy Market – Emerging Leader of Immuno Oncology
Release Date: 09 October 2019
As the incidence of cancer is increasing day by day, an intense demand of new therapeutics is rising and many new therapeutic approaches are being investigated for the development of noval therapeutics. Immuno Oncology is emerging as one...
Read More
IKS01 – A Lead ADC Shows Effectiveness in Tumor Regression
Release Date: 07 October 2019
On 30 September 2019, Iksuda Therapeutics announced the first data on its lead ADC in the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain. Iksuda is a developer of next generation Antibody Drug Conjuga...
Read More
Pegilodecakin and Checkpoint Inhibitors Combo shows Prominent Action in NSCLC and Kidney Cancer
Release Date: 07 October 2019
According to the findings of a recently performed study led by The University of Texas MD Anderson Cancer Center, Pegilodecakin in combination with two leading anti-PD-1 monoclonal antibodies i.e. pembrolizumab and nivolumab,...
Read More
Opdivo Enhances the Overall Survival of Patients with Esophageal Cancer
Release Date: 07 October 2019
According to the Phase III trial data of Opdivo (Nivolumab), it is able to improve the overall survival (OS) of patients in the case of esophageal squamous cell carcinoma (SCC). The findings of the study were published in the Lancet Onco...
Read More
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |
